Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
Background: Tivozanib (Fotivda) is an anti-angiogenic tyrosine kinase inhibitor that was denied access to the US market by the Food and Drug Administration (FDA). In contrast, it was granted approval by the European Medicines Agency (EMA) for the treatment of Renal Cell Carcinoma in adults. Given th...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioMed Central Ltd
2022
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |